MD3242887T2 - Compuși co-agonişti ai GIP și GLP-1 - Google Patents

Compuși co-agonişti ai GIP și GLP-1 Download PDF

Info

Publication number
MD3242887T2
MD3242887T2 MDE20170269T MD3242887T2 MD 3242887 T2 MD3242887 T2 MD 3242887T2 MD E20170269 T MDE20170269 T MD E20170269T MD 3242887 T2 MD3242887 T2 MD 3242887T2
Authority
MD
Moldova
Prior art keywords
gip
glp
agonist compounds
glucagon
diabetes
Prior art date
Application number
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Bengt Krister Bokvist
Tamer Coskun
Robert Chadwick Cummins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55315708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD3242887(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MD3242887T2 publication Critical patent/MD3242887T2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Prezenta invenţie se referă la compuşi peptidomimetici ai incretinei duali care agonizează receptorii atât pentru polipeptida insulinotropică dependentă de glucoză (GIP) umană cât şi peptida-1 asemănătoare glucagonului (GLP-1), şi pot fi utili pentru tratarea diabetului zaharat de tip 2 (T2D).
MDE20170269 2015-01-09 2016-01-05 Compuși co-agonişti ai GIP și GLP-1 MD3242887T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101488P 2015-01-09 2015-01-09
PCT/US2016/012124 WO2016111971A1 (en) 2015-01-09 2016-01-05 Gip and glp-1 co-agonist compounds

Publications (1)

Publication Number Publication Date
MD3242887T2 true MD3242887T2 (ro) 2019-11-30

Family

ID=55315708

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20170269 MD3242887T2 (ro) 2015-01-09 2016-01-05 Compuși co-agonişti ai GIP și GLP-1

Country Status (46)

Country Link
US (1) US9474780B2 (ro)
EP (2) EP3242887B1 (ro)
JP (3) JP6219534B2 (ro)
KR (5) KR20230023822A (ro)
CN (2) CN107207576B (ro)
AR (2) AR103242A1 (ro)
AU (1) AU2016205435B2 (ro)
CA (1) CA2973352C (ro)
CL (1) CL2017001760A1 (ro)
CO (1) CO2017006737A2 (ro)
CR (1) CR20170310A (ro)
CY (2) CY1122028T1 (ro)
DK (1) DK3242887T3 (ro)
DO (1) DOP2017000153A (ro)
EA (3) EA202090392A3 (ro)
EC (1) ECSP17043648A (ro)
ES (1) ES2747928T3 (ro)
FI (1) FIC20230005I1 (ro)
FR (1) FR23C1006I2 (ro)
HR (1) HRP20191614T1 (ro)
HU (2) HUE045860T2 (ro)
IL (4) IL281545B2 (ro)
JO (2) JO3575B1 (ro)
LT (2) LT3242887T (ro)
LU (1) LUC00296I2 (ro)
MA (2) MA50422A (ro)
MD (1) MD3242887T2 (ro)
ME (1) ME03494B (ro)
MX (2) MX382753B (ro)
MY (1) MY193616A (ro)
NL (1) NL301217I2 (ro)
NO (1) NO2023005I1 (ro)
NZ (3) NZ771043A (ro)
PE (1) PE20170954A1 (ro)
PH (1) PH12017501252B1 (ro)
PL (1) PL3242887T3 (ro)
PT (1) PT3242887T (ro)
RS (1) RS59146B1 (ro)
SG (1) SG11201705603YA (ro)
SI (1) SI3242887T1 (ro)
SV (1) SV2017005453A (ro)
TN (1) TN2017000198A1 (ro)
TW (1) TWI582109B (ro)
UA (1) UA118239C2 (ro)
WO (1) WO2016111971A1 (ro)
ZA (1) ZA201703930B (ro)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
EP3624828B1 (en) 2017-05-18 2024-08-07 Merck Sharp & Dohme LLC Pharmaceutical formulation comprising incretin-insulin conjugates
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
TWI744579B (zh) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
RU2020136305A (ru) * 2018-05-04 2022-05-05 Ново Нордиск А/С Производные gip и пути их применения
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
KR20210024583A (ko) * 2018-07-23 2021-03-05 일라이 릴리 앤드 캄파니 요법을 위한 gip/glp1 공효능제 사용 방법
AU2019309798A1 (en) * 2018-07-23 2021-02-11 Eli Lilly And Company Method of using a GIP/GLP1 co-agonist for diabetes
TWI735917B (zh) 2018-07-23 2021-08-11 美商美國禮來大藥廠 Gip/glp1共促效劑化合物
CN112534052B (zh) 2018-07-25 2024-09-20 奥美药业有限公司 全新il-21前药及使用方法
JP6564539B1 (ja) 2018-09-14 2019-08-21 長瀬産業株式会社 スルホン酸化合物によるペプチド精製方法
WO2020067575A1 (en) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
TWI799680B (zh) 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
GB201908424D0 (en) 2019-06-12 2019-07-24 Imp College Innovations Ltd Novel compounds
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
AR119471A1 (es) 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
EP4017866A1 (en) 2019-08-19 2022-06-29 Eli Lilly and Company Methods of making incretin analogs
WO2021066600A1 (ko) 2019-10-04 2021-04-08 한미약품 주식회사 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
CA3163507A1 (en) 2019-12-04 2021-06-10 The Scripps Research Institute Peptide conjugates and methods of use
AR120714A1 (es) * 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
JP7767290B2 (ja) 2020-01-11 2025-11-11 アスクジーン・ファーマ・インコーポレイテッド 新規なマスクされたサイトカインおよびその使用方法
IL294955A (en) * 2020-01-23 2022-09-01 Lilly Co Eli Cobalt-agonist gip/glp1 compounds
TW202140058A (zh) 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
CN115884982A (zh) 2020-03-06 2023-03-31 赛诺菲 作为选择性gip受体激动剂的肽
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
CN116113429A (zh) * 2020-07-06 2023-05-12 鸿绪生物医药科技（北京）有限公司 新型多肽及其治疗用途
CA3184723A1 (en) 2020-07-22 2022-01-27 Patrick J. KNERR Glp-1 and gip receptor co-agonists
AU2021312323A1 (en) 2020-07-22 2023-02-02 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
EP4222176A4 (en) * 2020-09-30 2024-02-28 Beijing QL Biopharmaceutical Co., Ltd. POLYPEPTIDE CONJUGATES AND METHODS OF USE
WO2022080986A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
BR112023003668A2 (pt) 2020-10-17 2023-04-25 Sun Pharmaceutical Ind Ltd Agonistas duplos de glp-1/gip
WO2022117056A1 (zh) * 2020-12-02 2022-06-09 南京明德新药研发有限公司 含内酰胺修饰的多肽类化合物
WO2022159395A1 (en) * 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2022177742A2 (en) 2021-02-17 2022-08-25 Eli Lilly And Company Tirzepatide therapeutic methods
JP2024508745A (ja) * 2021-02-17 2024-02-28 イーライ リリー アンド カンパニー Ｇｉｐ／ｇｌｐ１デュアルアゴニスト治療方法
US12215133B2 (en) 2021-03-25 2025-02-04 Brightgene Bio-Medical Technology Co., Ltd. GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
HRP20251468T1 (hr) * 2021-03-25 2026-01-02 Brightgene Bio-Medical Technology Co., Ltd. Agonist dvostrukog receptora gip i glp-1, farmaceutski pripravak i upotreba
KR20240004943A (ko) 2021-05-07 2024-01-11 일라이 릴리 앤드 캄파니 침식성 정제
IL308392A (en) 2021-05-13 2024-01-01 Carmot Therapeutics Inc G protein-coupled receptor modulators
CN117015551B (zh) * 2021-05-28 2024-05-28 广东众生睿创生物科技有限公司 多肽的制备及其应用
EP4345105A4 (en) * 2021-06-01 2025-04-23 Nanjing Zhihe Medicine Technology Co., Ltd Polypeptide derivative with dual targeted activation of GLP-1R and GIPR, manufacturing process therefor and use thereof
IL309067A (en) 2021-06-09 2024-02-01 Scripps Research Inst Long-acting dual gip/glp-1 peptide conjugates and methods of use
WO2022262825A1 (zh) * 2021-06-18 2022-12-22 南京明德新药研发有限公司 含内酰胺桥的多肽化合物
MX2024002845A (es) 2021-09-06 2024-04-30 Sanofi Sa Nuevos peptidos como agonistas potentes y selectivos del receptor de gip.
IL311411A (en) * 2021-09-15 2024-05-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250000948A1 (en) 2021-11-15 2025-01-02 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250019410A1 (en) 2021-11-22 2025-01-16 Sun Pharmaceutical Industries Ltd. Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CA3246912A1 (en) * 2022-04-07 2025-07-09 Guangdong Raynovent Biotech Co., Ltd. Pharmaceutical use of polypeptide in the preparation of medicates to treat and/or prevent diabetes, obesity and related diseases
CN116947978A (zh) * 2022-04-19 2023-10-27 北京惠之衡生物科技有限公司 一种glp-1和gip受体共激动多肽衍生物及其盐和制剂
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
CA3259912A1 (en) 2022-06-30 2024-01-04 Eli Lilly And Company Compositions of Tirzepatide and their use
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
IL318349A (en) * 2022-07-13 2025-03-01 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Glp-1/gip dual agonist, preparation method and use thereof
CA3262093A1 (en) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Pharmaceutical Formulations and Methods for the Treatment of Metabolic and Liver Disorders
CA3266547A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company COMPOSITIONS FOR ORAL ADMINISTRATION
WO2024059674A1 (en) 2022-09-15 2024-03-21 Eli Lilly And Company Gip and glp-1 dual agonist compounds
US20260103497A1 (en) * 2022-09-23 2026-04-16 Brightgene Pte. Ltd. Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
IL320036A (en) 2022-10-05 2025-06-01 Lilly Co Eli Peptides for incretin synthesis
CN117756913B (zh) * 2022-11-07 2025-05-09 内蒙古博睿精创科技有限公司 一种新型长效多肽化合物、组合物及其应用
AU2023385357A1 (en) * 2022-11-21 2025-06-05 Eli Lilly And Company Process for preparing a gip/glp1 dual agonist
AU2023397760A1 (en) 2022-12-16 2025-06-26 Peptron, Inc. Sustained-release microspheres including glp-1 receptor agonist or pharmaceutically acceptable salt thereof and use thereof
WO2024145638A2 (en) 2022-12-29 2024-07-04 Eli Lilly And Company Processes and intermediates for preparing tirzepatide
JP2026502943A (ja) 2022-12-30 2026-01-27 アルギファルマ エーエス 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
IL322205A (en) 2023-01-31 2025-09-01 Lilly Co Eli GIP/GLP1/GCG trireceptor agonists and their uses
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2024192219A1 (en) * 2023-03-15 2024-09-19 Viking Therapeutics, Inc. Pharmaceutical compositions and methods for the treatment of metabolic and liver disorders
CN118684758A (zh) * 2023-03-23 2024-09-24 上海民为生物技术有限公司 肠促胰岛素类似物及其应用
JP2026513204A (ja) 2023-03-31 2026-04-23 イーライ リリー アンド カンパニー Ｔ２ｄの治療に使用するためのチルゼパチド
WO2024213022A1 (zh) * 2023-04-11 2024-10-17 上海多米瑞生物技术有限公司 肠促胰素类似物及其制备方法和应用
WO2024243243A1 (en) * 2023-05-21 2024-11-28 Carmot Therapeutics Inc. Treatment of adults with overweight or obesity with or without weight-related comorbidities
CN116832141B (zh) * 2023-06-06 2024-02-09 诺博泰科(成都)生物科技有限公司 一种用于治疗糖尿病的glp-1、gip和gcg受体三激动多肽化合物
WO2024252366A1 (en) 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
TW202500183A (zh) 2023-06-15 2025-01-01 丹麥商諾佛 儂迪克股份有限公司 包括環糊精的醫藥調配物
KR20260032481A (ko) 2023-06-30 2026-03-09 질랜드 파마 에이/에스 병용 요법
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
CN117646017A (zh) * 2023-11-02 2024-03-05 中国人民解放军海军军医大学 Gip/glp-1双激动剂多肽编码基因、及其重组乳酸菌和应用
WO2025106773A1 (en) 2023-11-17 2025-05-22 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent
WO2025114501A1 (en) 2023-11-30 2025-06-05 Novo Nordisk A/S Tri-agonists of the glp-1, gip, and amylin receptors
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
CN120173084A (zh) * 2023-12-20 2025-06-20 深圳翰宇药业股份有限公司 一种替尔泊肽的合成方法
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025149039A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的药物组合物
WO2025163674A1 (en) * 2024-01-30 2025-08-07 Msn Laboratories Private Limited, R&D Center Process for the preparation of tirzepatide
WO2025185605A1 (en) * 2024-03-05 2025-09-12 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
WO2025191149A1 (en) 2024-03-15 2025-09-18 Krka, D.D., Novo Mesto Pharmaceutical composition comprising dual gip and glp-1 receptor agonist
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
WO2025237168A1 (zh) * 2024-05-11 2025-11-20 石药集团百克(山东)生物制药股份有限公司 Gipr和glp-1r共激动多肽及其用途
US20250352622A1 (en) 2024-05-15 2025-11-20 Rose Pharma Inc. Glp-1 formulations and their uses
CN118440155B (zh) * 2024-07-11 2024-11-22 中国药科大学 一种双激动多肽化合物及其医药用途
WO2026059846A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company Dissolving microneedle patch for transdermal delivery of a peptide
WO2026072611A1 (en) 2024-09-24 2026-04-02 Eli Lilly And Company Tirzepatide binding molecules, and uses thereof
WO2026073030A1 (en) 2024-09-27 2026-04-02 Carmot Therapeutics Inc. Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists
US12465697B1 (en) 2025-02-26 2025-11-11 Genzyme Corporation Medicament delivery device
US12539367B1 (en) 2025-02-26 2026-02-03 Genzyme Corporation Medicament delivery device
US12434008B1 (en) 2025-02-26 2025-10-07 Genzyme Corporation Lock ring for a medicament delivery device
US12420017B1 (en) 2025-02-26 2025-09-23 Genzyme Corporation Damping device for a medicament delivery device

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
JP5410020B2 (ja) * 2005-02-02 2014-02-05 ノヴォ ノルディスク アー／エス インスリン誘導体
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
KR20110043688A (ko) * 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체
JP5591243B2 (ja) 2008-09-12 2014-09-17 ノボ・ノルデイスク・エー／エス ペプチド又はタンパク質のアシル化の方法
CN101367873B (zh) * 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
RU2550696C2 (ru) 2008-12-19 2015-05-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Основанные на амидах пролекарства пептидов глюкагонового надсемейства
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
KR101091041B1 (ko) * 2010-07-29 2011-12-09 고려대학교 산학협력단 새로운 재조합 글루코스 의존성 인슐린분비 펩타이드(ｒｃＧＩＰ) 작용제 및 그 용도
CA2822617A1 (en) * 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
WO2012088116A2 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
US9453062B2 (en) 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
US9260503B2 (en) 2011-06-15 2016-02-16 Novo Nordisk A/S Multi-substituted insulins
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
KR20140114845A (ko) * 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
NZ702333A (en) * 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
EP2908845A1 (en) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Fatty acid acylated amino acids for growth hormone delivery
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
AR096440A1 (es) 2013-05-28 2015-12-30 Takeda Pharmaceuticals Co Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)

Also Published As

Publication number Publication date
KR20210145311A (ko) 2021-12-01
EP3242887A1 (en) 2017-11-15
EA031591B1 (ru) 2019-01-31
IL281545A (en) 2021-05-31
PL3242887T3 (pl) 2020-02-28
LTC3242887I2 (ro) 2024-10-10
JO3575B1 (ar) 2020-07-05
US20160199438A1 (en) 2016-07-14
JP2019203000A (ja) 2019-11-28
PH12017501252B1 (en) 2023-06-16
NZ771547A (en) 2024-12-20
CR20170310A (es) 2017-08-17
EA202090392A3 (ru) 2020-08-31
CY1122028T1 (el) 2020-10-14
MX2021005835A (es) 2021-07-15
CA2973352C (en) 2019-03-26
EA202090392A2 (ru) 2020-05-31
EA201791281A1 (ru) 2017-11-30
PH12017501252A1 (en) 2017-10-30
EP3597662A1 (en) 2020-01-22
MX2017008927A (es) 2017-10-11
LTPA2023504I1 (ro) 2023-02-27
MA41315A (fr) 2017-11-15
TN2017000198A1 (en) 2018-10-19
DOP2017000153A (es) 2017-07-15
ZA201703930B (en) 2019-06-26
CY2023003I2 (el) 2023-06-09
HUE045860T2 (hu) 2020-01-28
AU2016205435B2 (en) 2018-03-29
CN107207576A (zh) 2017-09-26
WO2016111971A1 (en) 2016-07-14
KR20190026967A (ko) 2019-03-13
CO2017006737A2 (es) 2017-09-29
KR20240135032A (ko) 2024-09-10
UA118239C2 (uk) 2018-12-10
KR20230023822A (ko) 2023-02-17
NO2023005I1 (no) 2023-02-02
MA41315B1 (fr) 2019-11-29
EA035055B1 (ru) 2020-04-22
LT3242887T (lt) 2019-11-11
JOP20200119A1 (ar) 2020-05-18
IL276492A (en) 2020-09-30
SI3242887T1 (sl) 2019-10-30
NL301217I1 (ro) 2023-02-15
SV2017005453A (es) 2018-08-27
SG11201705603YA (en) 2017-08-30
CY2023003I1 (el) 2023-03-24
TW201636362A (zh) 2016-10-16
JP6754867B2 (ja) 2020-09-16
TWI582109B (zh) 2017-05-11
KR101957620B1 (ko) 2019-03-13
AR103242A1 (es) 2017-04-26
FIC20230005I1 (fi) 2023-02-02
FR23C1006I2 (fr) 2024-01-05
EP3242887B1 (en) 2019-08-14
NZ755618A (en) 2024-12-20
CN112608377A (zh) 2021-04-06
RS59146B1 (sr) 2019-09-30
JP2017507124A (ja) 2017-03-16
FR23C1006I1 (fr) 2023-03-24
EA201892057A1 (ru) 2019-02-28
JP6545766B2 (ja) 2019-07-17
IL281545B2 (en) 2025-09-01
BR112017010596A2 (pt) 2018-03-06
AR131857A2 (es) 2025-05-07
IL252499B (en) 2020-08-31
MX382753B (es) 2025-03-13
ECSP17043648A (es) 2017-11-30
MY193616A (en) 2022-10-20
AU2016205435A1 (en) 2017-06-08
NZ732000A (en) 2018-11-30
JP2018052933A (ja) 2018-04-05
ES2747928T3 (es) 2020-03-12
PT3242887T (pt) 2019-10-29
CN112608377B (zh) 2024-02-13
IL281545B1 (en) 2025-05-01
HUS2300006I1 (hu) 2023-02-28
LUC00296I2 (ro) 2025-09-22
MA50422A (fr) 2020-08-26
CL2017001760A1 (es) 2018-03-16
IL320236A (en) 2025-06-01
IL252499A0 (en) 2017-07-31
HRP20191614T1 (hr) 2019-12-13
KR102330764B1 (ko) 2021-11-25
US9474780B2 (en) 2016-10-25
DK3242887T3 (da) 2019-09-02
CN107207576B (zh) 2020-11-24
KR20170092661A (ko) 2017-08-11
ME03494B (me) 2020-01-20
NZ771043A (en) 2024-12-20
JP6219534B2 (ja) 2017-10-25
NZ748274A (en) 2022-03-25
IL276492B (en) 2021-04-29
NL301217I2 (nl) 2023-04-04
CA2973352A1 (en) 2016-07-14
PE20170954A1 (es) 2017-07-13

Similar Documents

Publication Publication Date Title
JOP20200119A1 (ar) مركبات مساعد مشترك من gip وglp-1
SA518391903B1 (ar) معاضد مستقبل جلوكاجون/الببتيد 1 المشابه للجلوكاجون/البولي ببتيد المحب للأنسولين المعتمد على الجلوكوز الثلاثي
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MY197569A (en) Gip/glp1 co-agonist compounds
MY205796A (en) Gipr-agonist compounds
EA035466B9 (ru) Соединения и способы на основе двойного агониста гип и гпп-1
EP4058445A4 (en) Glp-1 receptor agonist and use thereof
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
NZ740644A (en) Glucagon receptor agonists
MX2020003217A (es) Coagonistas de accion prolongada de los receptores de glucagon y glp-1.
UA118558C2 (uk) Пептидна сполука
ZA202507395B (en) Semaglutide in cardiovascular conditions
MX394179B (es) Liraglutida en afecciones cardiovasculares.
MX2015009433A (es) Polipeptidos novedosos que tienen actividad liberadora de hormonas de la saciedad.